{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Severe non-hematologic adverse events were defined as adverse events grade 3 or higher, regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0)","groups":[{"description":"Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\\^2)","id":"OG000","title":"Anti-thymocyte Globulin/Melphalan"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"every month during treatment, up to 12 months","title":"Number of Participants With Severe Non-hematological Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}